Literature DB >> 12051772

Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls.

Tie-hua Sun1, Douglas B Heimark, Thang Nguygen, Jerry L Nadler, Joseph Larner.   

Abstract

Previous data from our and other labs demonstrated a decreased chiro-inositol content in urine and tissues of human subjects and animals with type 2 diabetes. In urine this decrease in chiro-inositol was accompanied by an increase in myo-inositol content. Decreased urine levels of chiro-inositol in monkeys were next correlated with the severity of underlying insulin resistance determined by five separate assays. To investigate the decreased chiro-inositol and the accompanying increased myo-inositol excretions in urine in humans and monkeys, we postulated a defect in the epimerization of myo-inositol to chiro-inositol. [(3)H]Myo-inositol was then shown to be converted to [(3)H]chiro-inositol in rats in vivo and in fibroblasts in vitro in a process stimulated by insulin. We next demonstrated that the conversion of [(3)H]myo-inositol to [(3)H]chiro-inositol in vivo was markedly decreased in GK type 2 diabetic rats compared to Wistar controls in liver, muscle, and fat, insulin sensitive tissues. Decreases of 20-25% conversion to baseline levels of under 5% conversion were observed. In the present work, we initially compared the total contents of myo-inositol and chiro-inositol in GK type 2 diabetic rat kidney, liver, and muscle compared to Wistar controls. We demonstrated a consistent decreased total chiro-inositol to myo-inositol ratio in kidney, liver, and muscle compared to controls. We next established the presence of a myo-inositol to chiro-inositol epimerase activity in rat liver cytosol. Enzyme activity was shown to be time and enzyme concentration dependent with a broad pH optimum. It required NADH and NADPH for full activity, which is compatible with its action via an oxido-reductive mechanism. Lastly, we demonstrated that the epimerase enzyme bioactivity was significantly decreased in muscle, liver, and fat cytosolic extracts of GK type 2 diabetic rats versus Wistar controls. Decreased myo-inositol to chiro-inositol epimerase activity may therefore play a role in explaining the decreased chiro-inositol to myo-inositol urine and tissue ratios observed here and in previous animal and human studies. Further it may also possibly play a role in the underlying insulin resistance. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051772     DOI: 10.1016/S0006-291X(02)00313-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide.

Authors:  N R F Nascimento; L M A Lessa; M R Kerntopf; C M Sousa; R S Alves; M G R Queiroz; J Price; D B Heimark; J Larner; X Du; M Brownlee; A Gow; C Davis; M C Fonteles
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

Review 2.  Conservation and innovation in Tetrahymena membrane traffic: proteins, lipids, and compartments.

Authors:  Alejandro D Nusblat; Lydia J Bright; Aaron P Turkewitz
Journal:  Methods Cell Biol       Date:  2012       Impact factor: 1.441

3.  Inositol, glycogen, insulin, and six nobelists.

Authors:  Joseph Larner
Journal:  J Biol Chem       Date:  2013-03-20       Impact factor: 5.157

Review 4.  D-chiro-inositol glycans in insulin signaling and insulin resistance.

Authors:  Joseph Larner; David L Brautigan; Michael O Thorner
Journal:  Mol Med       Date:  2010-08-27       Impact factor: 6.354

5.  D-chiro-inositol negatively regulates the formation of multinucleated osteoclasts by down-regulating NFATc1.

Authors:  Jungeun Yu; Seunga Choi; Eui-Soon Park; Bongjin Shin; Jiyeon Yu; Seoung Hoon Lee; Masamichi Takami; Jong Soon Kang; Hyungun Meong; Jaerang Rho
Journal:  J Clin Immunol       Date:  2012-06-19       Impact factor: 8.317

6.  Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.

Authors:  Jean-Patrice Baillargeon; Maria J Iuorno; Teimuraz Apridonidze; John E Nestler
Journal:  Metab Syndr Relat Disord       Date:  2010-04       Impact factor: 1.894

7.  Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples.

Authors:  Karen J Schimpf; Claudia C Meek; Richard D Leff; Dale L Phelps; Daniel J Schmitz; Christopher T Cordle
Journal:  Biomed Chromatogr       Date:  2015-05-26       Impact factor: 1.902

8.  Quantitative determination of free glycerol and myo-inositol from plasma and tissue by high-performance liquid chromatography.

Authors:  Ryan A Frieler; Dane J Mitteness; Mikhail Y Golovko; Heidi M Gienger; Thad A Rosenberger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-09-19       Impact factor: 3.205

9.  Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylation.

Authors:  April J Stull; John P Thyfault; Mark D Haub; Richard E Ostlund; Wayne W Campbell
Journal:  Metabolism       Date:  2008-11       Impact factor: 8.694

10.  Placental Inositol Reduced in Gestational Diabetes as Glucose Alters Inositol Transporters and IMPA1 Enzyme Expression.

Authors:  Reshma A Pillai; Mohammed O Islam; Preben Selvam; Neha Sharma; Anne H Y Chu; Oliver C Watkins; Keith M Godfrey; Rohan M Lewis; Shiao Y Chan
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.